• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Header Right

Search

  • Home
  • Expertise
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Executive Team
      • Study Management
    • History
    • Careers
    • Privacy policy / GDPR
  • Contact

Klaas Heinemann

Managing Director

Klaas Heinemann

Klaas Heinemann is a physician and epidemiologist who has headed ZEG Berlin since 2009 and sits on the Kantar Health Europe management board.  The principal investigator for many studies, Klaas provides strategic direction as ZEG-Berlin diversifies beyond women’s health studies to bring its data methodology to other realms of health.

 

Klaas trained in internal medicine at Charite University Hospital, Berlin before completing postgraduate masters degrees in business and administration (Berlin School of Economics, Berlin), and epidemiology (London School of Hygiene and Tropical Medicine, London). Prior to his appointment as managing director, Klaas was an external consultant for ZEG Berlin. Previously he worked in the US and Germany as a Medical Expert in Global Medical Affairs at Schering AG and later Bayer Pharma, planning and managing clinical research focusing on Phase III clinical studies and post-market phase IV study design.

Publications

Heinemann Klaas, Imthurn Bruno, Marions Lena, Gerlinger Christoph, Becker Kerstin, Möhner Sabine, Faustmann Thomas, Safety of Dienogest and Other Hormonal Treatments for Endometriosis in Real-World Clinical Practice (VIPOS): A Large Noninterventional Study Advances in Therapy. 2020; 2528-2537. 10.1007/s12325-020-01331-z.
Möhner Sabine, Becker Kerstin, Lange Jens, von Stockum Sophia, Heinemann Klaas, Risk of depression and anemia in users of hormonal endometriosis treatments: Results from the VIPOS study European Journal of Obstetrics &Gynecology and Reproductive Biology. 2020; 212 - 217. 10.1016/j.ejogrb.2020.05.049.
Dinger Jürgen, Möhner Sabine, Heinemann Klaas, Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study. Frontiers in Women's Health. 2020; Vol. 5: 1-8. 10.15761/FWH.1000178.
Download PDF: Jürgen-et-al.-2020_Results-from-the-extended-INAS-SCORE-study.pdf
Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Grimes David A., Heinemann Klaas, Comparing the Cardiovascular Risk of Norethindrone Acetate & Levonorgestrel Pills: Is There a Difference? [10I]. Obstetrics & Gynecology. 2020; Volume 135 - Issue - p 94S. 10.1097/01.AOG.0000664136.96902.7e.
Reed Suzanne, Do Minh Thai, Lange Jens, Koro Carol, Fox Michelle, Heinemann Klaas, Real world data on Nexplanon® procedure-related events: final results from the Nexplanon observational risk assessment study (NORA) Contraception. 2019; pii: S0010-7824(19)30131-3. 10.1016/j.contraception.2019.03.052.
Barnett Clare, Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study Contraception & Reproductive Health Care. 2019; 1-4. 10.1080/13625187.2019.1629412.
Barnett Clare, Möhner Sabine, Do Minh Thai, Heinemann Klaas, Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study The European Journal of Contraception and Reproductive Health Care. 2018; page 1-5.
Heinemann Klaas, Barnett Clare, Reed Suzanne, Möhner Sabine, Do Minh Thai, IUD use among parous women and risk of uterine perforation: a secondary analysis Contraception. 2017; Volume 95, Issue 6, Pages 605–607.
Heinemann Klaas, Pauls Karl, Drug Utilization Study on the Prescribing Indications for CPA/EE (Cyproterone acetate 2mg in combination with Ethinylestradiol 35mcg) in 5 European Countries Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue S2, Pages 1-674.
Hagemann Christine, Heinemann Klaas, Möhner Sabine, Safety and efficacy of intrauterine devices: Baseline characteristics of 32,022 study participants from the EURAS-LCS12 study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.
Bauerfeind Anja, Möhner Sabine, Do Minh Thai, Heinemann Klaas, The Influence of Women’s Educational Level on Unintended Pregnancy Rates amongst Users of Combined Oral Contraceptives Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.
Heinemann Klaas, Dinger Jürgen, Do Minh Thai, Franke Christian, Unintended Pregnancies in Users of Different Combined Oral Contraceptives – Final results from the INAS-SCORE Study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.
Heinemann Klaas, Dinger Jürgen, Do Minh Thai, Franke Christian, Cardiovascular Safety in Users of Different Combined Oral Contraceptives – Final results from the INAS-SCORE Study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.
Barnett Clare, Bauerfeind Anja, Do Minh Thai, Heinemann Klaas, Influence of age and BMI on risk of venous thromboembolism: a meta-analysis of 246,513 women using combined oral contraceptives based on 521,516 women-years. Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.
Bauerfeind Anja, Barnett Clare, Do Minh Thai, Heinemann Klaas, The effect of BMI on unintended pregnancy rates amongst users of combined oral contraceptives Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.
Heinemann Klaas, Möhner Sabine, Reed Suzanne, Do Minh Thai, Unwanted pregnancies in women using Intrauterine Devices: final results from the EURAS-IUD 5-years study Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.
Heinemann Klaas, Möhner Sabine, Do Minh Thai, Reed Suzanne, Intrauterine Devices and the Risk of Uterine Perforations: Final Results from the EURAS-IUD 5-years study Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.
Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Impact of Estrogen Type on Cardiovascular Safety of Combined Oral Contraceptives Contraception. 2016; Oct;94(4):328-39. 10.1016/j.contraception.2016.06.010.
Barnett Clare, Hagemann Christine, Dinger Jürgen, Heinemann Klaas, Fertility and combined oral contraceptives - unintended pregnancies and planned pregnancies following oral contraceptive use - results from the INAS-SCORE study Eur J Contracept Reprod health Care. 2016; Oct 17:1-7. 10.1080/13625187.2016.1241991.
Heinemann Klaas, Reed Suzanne, Möhner Sabine, Do Minh Thai, Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015; Apr;91(4):280-3. 10.1016/j.contraception.2015.01.011.
Bardenheuer Kristina, Heinemann Klaas, Do Minh Thai, Franke Christian, Cardiovascular Safety in Users of Different Combined Oral Contraceptives - Final Results from the INAS-SCORE study Pharmac. 2015; (24) S1, 1–587. 10.1002/pds.3838.
Heinemann Klaas, Reed Suzanne, Möhner Sabine, Do Minh Thai, Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015; 10.1016/j.contraception.2015.01.007.
Dinger Jürgen, Bardenheuer Kristina, Heinemann Klaas, Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014; Apr; 89(4): 253–63.. 10.1016/j.contraception.2014.01.023.
Reed Suzanne, Heinemann Klaas, Dinger Jürgen, Baseline risk factors for cardiovascular events: differences between the USA and Russia in a study population of combined oral contraceptives Pharmacoepidemiology and Drug Safety. 2014; Sep; 23(S1): 1-497. 10.1002/pds.3701.
Heinemann Klaas, Dinger Jürgen, Bardenheuer Kristina, Reed Suzanne, The safety of oral contraceptives in adolescents. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Heinemann Klaas, Reed Suzanne, Möhner Sabine, Ectopic pregnancies under IUD use: interim results from the EURAS-IUD study Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Heinemann Klaas, Reed Suzanne, Möhner Sabine, Breastfeeding as as risk factor for uterine preforation during IUD insertion: interim results from the ERUAS-IUD study Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Möhner Sabine, Dinger Jürgen, Heinemann Klaas, Transatlantic active surveillance of cardiovascular safety (TASC) of an Etonogestrel/Ethinylestradiol-containing vaginal ring. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Heinemann Klaas, Assmann Anita, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 365. DOI 10.1002.
Heinemann Klaas, Assmann Anita, Möhner Sabine, Long term active surveillance study for oral contraceptives (LASS): final results on cardiovascular safety. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 360. DOI 10.1002.
Heinemann Klaas, Reed Suzanne, Dinger Jürgen, Intrauterine devices and risk of uterine perforations: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S2) 45. DOI 10.1002.
Heinemann Lothar A , Do Minh Thai, Heinemann Klaas, Lindemann M , Filonenko A, Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women International. 2012; Feb;33(2):109-24.
Dennerstein L, Lehert P, Heinemann Klaas, Epidemiology of premenstrual symptoms and disorders. Menopause International. 2012; Jun;18(2):48-51.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and the risk of uterine perforation: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 233.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 181.
Heinemann Klaas, Barnett Clare, Dinger Jürgen, Risk factors for uterine perforations during IUD insertion: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 138.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Complications associated with unintended pregnancies under IUD use: results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 125.
Dennerstein L, Lehert P, Heinemann Klaas, Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause International. 2011; Sep: 17(3):96-101. 10.1258/mi.2011.011028.
Dennerstein L, Lehert P, Heinemann Klaas, Global study of women's experiences of premenstrual symptoms and their effects on daily life. Menopause International. 2011; Sep: 17(3):88-95. 10.1258/mi.2011.011027.
Heinemann Klaas, Heinemann Lothar A , Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.. J Fam Plann Reprod Health Care. 2011; Jul;37(3):132-5. 10.1136/jfprhc-2011-14524.
Heinemann Klaas, EURAS-HRT: study design and baseline characteristics - international menopause society. The Journal of Adult Women`s Health & Medicine. 2011; Vol. 14 Supplement 1: 214.
Bardenheuer Kristina, Dinger Jürgen, Assmann Anita, Heinemann Klaas, Leddin Janko, Drug utilization study on the prescribing indications of oral contraceptives in croatia. Pharmacoepidemiology and Drug Safety. 2010; 19:S55.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: Interim results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2010; 19:S31-32.
Heinemann Klaas, Problems associated with comprehensive detection/validation of unexpected ADRs in a population. PRM Newsletter. 2010; Apr 2010;5:1-3,9-1.
Dennerstein L, Lehert P, Bäckström T, Heinemann Klaas, The effect of premenstrual symptoms on activities of daily life. Fertil Steril. 2010; Aug;94(3):1059-64.. 10.1016/j.fertnstert.2009.04.023.
Dennerstein L, Lehert P, Bäckström T, Heinemann Klaas, Premenstrual symptoms - severity, duration and typology: an international cross-sectional study Menopause International. 2009; Sep;15(3):120-6. 10.1258/mi.2009.009030.
Bäckström T, Heinemann Klaas, Nyberg S, Hammarbäck S, Definition and prevalence of premenstrual syndromes. Gynaecology Forum. 2009; 14(3).
Heinemann Klaas, Rübig A, Strothmann A, Nahum GG, Heinemann Lothar A , Prevalence and opinions of hormone therapy prior to the Women’s Health Initiative: a multinational survey in four continents. J Women’s Health. 2008; 17:1-16.
Heinemann Klaas, Saad F, Wiesemes M, Heinemann Lothar A , Expectations towards a novel MFC and potential user types. Results of a multinational survey. J Andrology. 2005; 26(2): 155-62.
Heinemann Klaas, Saad F, Wiesemes M, Heinemann Lothar A , Attitudes toward male fertility control; a multinational survey in four continents. Human Reproduction. 2005; 20 (2): 549-56.
Heinemann Lothar A , Potthoff P, Heinemann Klaas, Pauls Alfred, Ahlers C J, Saad F, Scale for Quality of Sexual Function (QSF) as an outcome measure for both genders?. J Sex Med. 2005; 2:82-95.
Heinemann Lothar A , Saad F, Heinemann Klaas, Do Minh Thai, Can results of the AMS scale predict those of screening scales for androgen deficiency?. Aging Male. 2004; 7:211-18.
Heinemann Klaas, Alexander Ruebig Alexander, Potthoff P, Schneider HPG, Strelow Frank, Heinemann Lothar A , Do Minh Thai, The Menopause Rating Scale: A methodological review. Health and Quality of Life Outcomes. 2004; 2:45 (2 September 2004). 10.1186/1477-7525-2-45.
Heinemann Klaas, Thiel C, Möhner Sabine, Lewis Michael, Raff T, Heinemann Lothar A , Benign gynecological tumors: estimated incidence. Results of the German Cohort study on Women’s Health Eur J Obst Gyn Reprod Biol. 2003; 107: 78-80.
Heinemann Klaas, Saad F, Sweating attacks: key symptom in menopausal transition only for women? Eur Urol. 2003;
Heinemann Klaas, Möhner Sabine, Assmann Anita, Lewis Michael, Garbe E, Heinemann Lothar A , Teichmann A T, Trend der HRT Nutzung in Deutschland 1980-1999. Ergebnisse der Deutschen Kohortenstudie zur Frauengesundheit. 2002; 43:508-511.
Heinemann Klaas, Möhner Sabine, Lewis Michael, Assmann Anita, Garbe E, Heinemann Lothar A , Trend der OC-Nutzung in einer Deutschen Frauen-Kohorte 1980-1999 Zentralbl Gynakol. 2002; 124(2): 128-131. DOI: 10.1055/s-2002-24241.
Heinemann Klaas, Heinemann Lothar A , Assmann Anita, Möhner Sabine, Schneider HPG, Reliabilität der Menopause-Rating-Skala (MRS). Untersuchung für die Deutsche Bevölkerung Zentralbl Gynakol. 2002; 124(3): 161-163. DOI: 10.1055/s-2002-32268.
Heinemann Lothar A , Möhner Sabine, Assmann Anita, Heinemann Klaas, Use of oral contraceptives containing dienogest and risk of venous thromboembolism; an extended summary report. Life and Medical Science Online. 2001; 2.
Potthoff P, Heinemann Klaas, Schneider HPG, osemeier HP, Hauser G A, Menopause-Rating Skala (MRS II): Methodische Standardisierung in der deutschen Bevoelkerung Zentralbl Gynakol. 2000; 122(5):280-6..
Heinemann Klaas, Heinemann Lothar A , Do Minh Thai, Möhner M, Heuchert G E, Occupational exposure and liver cancer in women: results of the Multicentre International Liver Tumour Study (MILTS). Occup Med (Lond). 2000; Aug;50(6):422-9.

sidebar

Executive Team

  • Klaas Heinemann
  • Christine Hagemann
  • Sabine Möhner
  • Clare Barnett
  • Alfred Pauls
  • Jürgen Dinger
  • Johanna Poppe

Study Management

  • Clare Barnett
  • Divine Akumo
  • Pauline De Corte
  • Christine Hagemann
  • Suzanne Reed
  • Janina Flume
  • Anja Bauerfeind
  • Do Minh Thai
  • Sabine Möhner
  • Karl Pauls
  • Klaas Heinemann

Who We Are

ZEG Berlin is a private research institute specialized in conducting post-authorization safety / efficacy studies using primary data collection methods. From protocol development to the final publication of study results, we believe in entering into a collaborative partnership with our clients, striving to develop study designs that are best equipped to deliver quality data that accurately answers the question at hand.

Our specialized team of highly-skilled physicians, epidemiologists and statisticians has extensive experience in the design of studies for complex epidemiological questions and is ready to assist you in developing studies that are best suited to your needs. We are a full-service institute, offering all components for post-authorization medical research – from study design to project implementation, study conduct and the publication and presentation of results.

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Diagnostic tools
  • Data collection instruments

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2021 ZEG Berlin

Impressum

Website by Laura Yeffeth

This site uses cookies: Find out more.